selegiline

Summary

Summary: A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.

Top Publications

  1. ncbi Neuroprotective actions of selegiline
    M Ebadi
    Department of Pharmacology, Physiology, and Therapeutics, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota 58203, USA
    J Neurosci Res 67:285-9. 2002
  2. doi Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG
    Stephen F Carter
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    J Nucl Med 53:37-46. 2012
  3. doi Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography
    Balazs Gulyas
    Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden
    Neurochem Int 58:60-8. 2011
  4. doi The pharmacology of selegiline
    Kálmán Magyar
    Department of Pharmacodynamics, Semmelweis University, Budapest, Hungary
    Int Rev Neurobiol 100:65-84. 2011
  5. ncbi Selegiline modifies the extinction of responding following morphine self-administration, but does not alter cue-induced reinstatement, reacquisition of morphine reinforcement, or precipitated withdrawal
    Kenneth Grasing
    Substance Abuse Research Laboratory, Kansas City Veterans Affairs Medical Center, 4801 Linwood Boulevard, Kansas City, MO 64128, USA
    Pharmacol Res 51:69-78. 2005
  6. ncbi A hypertensive reaction induced by concurrent use of selegiline and dopamine
    L M Rose
    Department of Pharmacy, Fairview Hospital, Cleveland, OH 44111, USA
    Ann Pharmacother 34:1020-4. 2000
  7. ncbi Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension
    K F Bhattacharya
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Parkinsonism Relat Disord 9:221-4. 2003
  8. ncbi Cardiopulmonary effects of medetomidine, oxymorphone, or butorphanol in selegiline-treated dogs
    John R Dodam
    Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, 379 East Campus Drive, Columbia, MO 65211, USA
    Vet Anaesth Analg 31:129-37. 2004
  9. pmc Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts
    Chitra Sridar
    Department of Pharmacology, The University of Michigan, Ann Arbor, MI, USA
    Drug Metab Dispos 40:2256-66. 2012
  10. ncbi Selegiline treatment after transient global ischemia in gerbils enhances the survival of CA1 pyramidal cells in the hippocampus
    H Lahtinen
    A I Virtanen Institute, University of Kuopio, Finland
    Brain Res 757:260-7. 1997

Detail Information

Publications211 found, 100 shown here

  1. ncbi Neuroprotective actions of selegiline
    M Ebadi
    Department of Pharmacology, Physiology, and Therapeutics, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota 58203, USA
    J Neurosci Res 67:285-9. 2002
    b>Selegiline, a selective inhibitor of monoamine oxidase-B (MAO-B), was one of the first adjunct therapies in clinical neurology...
  2. doi Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG
    Stephen F Carter
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    J Nucl Med 53:37-46. 2012
    ..Along with (11)C-DED PET, (11)C-Pittsburgh compound B ((11)C-PIB; fibrillar Aβ deposition), (18)F-FDG (glucose metabolism), T1 MRI, cerebrospinal fluid, and neuropsychologic data were acquired from the patients...
  3. doi Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography
    Balazs Gulyas
    Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden
    Neurochem Int 58:60-8. 2011
    ..In the present study [(11)C]-L-deprenyl, the PET radioligand version of L-deprenyl or selegiline®, a selective irreversible MAO-B inhibitor was used in whole hemisphere autoradiographic experiments in human ..
  4. doi The pharmacology of selegiline
    Kálmán Magyar
    Department of Pharmacodynamics, Semmelweis University, Budapest, Hungary
    Int Rev Neurobiol 100:65-84. 2011
    b>Selegiline, the R-optical enantiomer of deprenyl (phenyl-isopropyl-methyl-propargylamine), was almost exclusively used MAO-B inhibitor during the past decades to treat Parkinson's disease...
  5. ncbi Selegiline modifies the extinction of responding following morphine self-administration, but does not alter cue-induced reinstatement, reacquisition of morphine reinforcement, or precipitated withdrawal
    Kenneth Grasing
    Substance Abuse Research Laboratory, Kansas City Veterans Affairs Medical Center, 4801 Linwood Boulevard, Kansas City, MO 64128, USA
    Pharmacol Res 51:69-78. 2005
    b>Selegiline is an irreversible inhibitor of monoamine oxidase (MAO) with psychostimulant and neuroprotective effects which can prevent decreases in dopamine efflux that follow opiate withdrawal...
  6. ncbi A hypertensive reaction induced by concurrent use of selegiline and dopamine
    L M Rose
    Department of Pharmacy, Fairview Hospital, Cleveland, OH 44111, USA
    Ann Pharmacother 34:1020-4. 2000
    To describe a hypertensive reaction induced by concurrent use of selegiline and dopamine.
  7. ncbi Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension
    K F Bhattacharya
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Parkinsonism Relat Disord 9:221-4. 2003
    Less than a consensus exists as to whether chronic treatment with selegiline in combination with levodopa/carbidopa in patients with Parkinson's disease, is associated with more pronounced orthostatic hypotension than treatment with ..
  8. ncbi Cardiopulmonary effects of medetomidine, oxymorphone, or butorphanol in selegiline-treated dogs
    John R Dodam
    Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, 379 East Campus Drive, Columbia, MO 65211, USA
    Vet Anaesth Analg 31:129-37. 2004
    To determine if chronic selegiline HCl administration affects the cardiopulmonary response to medetomidine, oxymorphone, or butorphanol in dogs.
  9. pmc Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts
    Chitra Sridar
    Department of Pharmacology, The University of Michigan, Ann Arbor, MI, USA
    Drug Metab Dispos 40:2256-66. 2012
    b>Selegiline, the R-enantiomer of deprenyl, is used in the treatment of Parkinson's disease. Bupropion, an antidepressant, often used to treat patients in conjunction with selegiline, is metabolized primarily by CYP2B6...
  10. ncbi Selegiline treatment after transient global ischemia in gerbils enhances the survival of CA1 pyramidal cells in the hippocampus
    H Lahtinen
    A I Virtanen Institute, University of Kuopio, Finland
    Brain Res 757:260-7. 1997
    b>Selegiline (L-deprenyl) has shown neuroprotective effects in a variety of degenerative processes...
  11. ncbi Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study
    Arad Kodesh
    Lev Hasharon Mental Health Medical Center, Pardessiya, Israel
    Clin Neuropharmacol 26:193-5. 2003
    ..undertaken in 10 neuroleptic-treated male schizophrenic outpatients to assess the effect of coadministration of selegiline 15 mg/day for 3 weeks on their sexual dysfunction...
  12. ncbi Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms
    William G Ondo
    Baylor College of Medicine, Department of Neurology, 6550 Fannin, Houston, TX 77030, USA
    Clin Neuropharmacol 30:295-300. 2007
    b>Selegiline orally disintegrating tablet (ODT; Zelapar) is a selective monoamine oxidase B inhibitor developed as an adjunct to levodopa (LD) for Parkinson disease...
  13. ncbi Selegiline induces neuronal phenotype and neurotrophins expression in embryonic stem cells
    Fariba Esmaeili
    Department of Anatomical Sciences, School of Medical Sciences, Tarbiat Modarres University, Tehran, Iran
    Rejuvenation Res 9:475-84. 2006
    The antiaging effect of selegiline was reported by several investigators; therefore, there is a growing interest in the potential use of stem cell therapy in aging...
  14. ncbi Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease
    T H Haapaniemi
    Department of Neurology, University of Oulu, PL 5000, 90014 Oulu, Finland
    J Neurol 247:868-74. 2000
    ..in 60 untreated PD patients randomised to receive either levodopa (n = 20), bromocriptine (n = 20) or selegiline (n = 20) as their initial treatment. The results were compared with those of 28 healthy controls...
  15. ncbi Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study
    Afshar Amiri
    Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran
    Hum Psychopharmacol 23:79-86. 2008
    It has been reported that selegiline, a Selective Monoamine Oxidase Inhibitor B (MAOI-B), at low doses would be helpful for treating negative symptoms in schizophrenia. Nevertheless, the results are contradictory so far...
  16. ncbi Changes in vascular alpha 1- and alpha 2-adrenoceptor responsiveness by selegiline treatment
    M Pelat
    , INSERM U 317, , , BP 72002, 31073 Toulouse cedex 7, France
    Fundam Clin Pharmacol 15:239-45. 2001
    Pharmacoepidemiological studies have reported an excess of mortality with selegiline, a MAO B inhibitor used in the treatment of Parkinson's disease...
  17. ncbi Clinical pharmacokinetics and pharmacodynamics of selegiline. An update
    I Mahmood
    Division of Pharmaceutical Evaluation I, Food and Drug Administration, Rockville, Maryland, USA
    Clin Pharmacokinet 33:91-102. 1997
    b>Selegiline is a selective inhibitor of monoamine oxidase-B (MAO-B) at a dose of 10 mg/day and is given to patients with Parkinson's disease as an adjunct to levodopa therapy...
  18. ncbi Selegiline treatment facilitates recovery after stroke
    J Sivenius
    Department of Neuroscience and Neurology, University of Kuopio, Finland
    Neurorehabil Neural Repair 15:183-90. 2001
    b>Selegiline (L-deprenyl) is a selective monoamine oxidase B (MAO-B) inhibitor used in the treatment of Parkinson's disease. In addition, it is thought to rescue neurons with a loss of target-derived trophic support...
  19. doi Selegiline is an efficient and potent inducer for bone marrow stromal cell differentiation into neuronal phenotype
    Mohammad Taghi Ghorbanian
    Department of Anatomical Sciences, School of Medical Sciences, Tarbiat, Modares University, Tehran, Iran
    Neurol Res 32:185-93. 2010
    ..Many of these chemicals were reported to be of mutagenic, teratogenic or carcinogenic properties. The purpose of this work was to evaluate the neuronal inductivity of selegiline to BMSCs.
  20. ncbi Transdermal selegiline
    Ashwin A Patkar
    Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC 27705, USA
    Drugs Today (Barc) 43:361-77. 2007
    ..Efforts to address these safety issues led to the development of a transdermal formulation of selegiline, called selegiline transdermal system (STS). STS has been approved by the U.S...
  21. ncbi Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases
    Manuchair Ebadi
    Department of Pharmacology, University of North Dakota, School of Medicine and Health Sciences, Grand Forks, ND 58203, USA
    Curr Drug Targets 7:1513-29. 2006
    b>Selegiline inhibits the activity of monoamine oxidase B, enhances the release of dopamine, blocks the uptake of dopamine, acts as a calmodulin antagonist, and enhances the level of cyclic AMP, which in turn protects dopaminergic neurons...
  22. ncbi Selegiline protects against recognition memory impairment induced by neonatal iron treatment
    Maria Noemia Martins de Lima
    Programa de Pós Graduação em Gerontologia Biomédica, Instituto de Geriatria e Gerontologia, Hospital Sao Lucas, Pontificia Universidade Catolica do Rio Grande do Sul, 90619 900 Porto Alegre, RS, Brazil
    Exp Neurol 196:177-83. 2005
    ..The aim of the present study was to determine whether selegiline, a monoamine oxidase (MAO) inhibitor known for its neuroprotective properties, could protect rats against ..
  23. ncbi Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial
    Shahin Akhondzadeh
    Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Avenue, Tehran 13334, Iran
    Prog Neuropsychopharmacol Biol Psychiatry 27:841-5. 2003
    ..b>Selegiline is a type B monoamine oxidase inhibitor (MAOI) that is metabolized to amphetamine and methamphetamine stimulant ..
  24. doi The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species
    Carolina A Braga
    Instituto de Bioquimica Medica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941 590, Brazil
    J Mol Biol 405:254-73. 2011
    ..b>Selegiline (Sel) is a noncompetitive monoamino oxidase B inhibitor that has neuroprotective effects and has been ..
  25. ncbi Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial
    Mohammad Reza Mohammadi
    Department of Psychiatry, Tehran University of Medical Sciences, Psychiatry and Clinical Psychology Research Center, Roozbeh Hospital, Tehran, Iran
    J Child Adolesc Psychopharmacol 14:418-25. 2004
    The aim of this study was to examine the selegiline treatment compared to methylphenidate (MPH) in children and adolescents with attention deficit hyperactivity disorder (ADHD).
  26. ncbi Freezing of gait in PD: prospective assessment in the DATATOP cohort
    N Giladi
    Movement Disorders Division, Department of Neurology, Columbia-Presbyterian Medical Center, New York, NY, USA
    Neurology 56:1712-21. 2001
    ..Deprenyl, in the absence of L-dopa, was found to be an effective prophylactic treatment and should be considered for patients with PD who have an onset of gait difficulty...
  27. doi Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration
    Wen Zhu
    Department of Neurology, The 1st Affiliated Hospital of Sun Yat sen University, Guangzhou, China
    J Neurochem 105:1970-8. 2008
    ..Rasagiline and selegiline are selective and irreversible monoamine oxidase-B inhibitors that possess significant protective properties on ..
  28. ncbi Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study
    Cheryl H Waters
    Department of Neurology, Columbia University, New York, New York 10032, USA
    Mov Disord 19:426-32. 2004
    Zydis selegiline dissolves on contact with saliva and undergoes pregastric absorption. This minimizes first-pass metabolism and provides high plasma concentrations of selegiline...
  29. ncbi Selegiline transdermal system in major depressive disorder: profile report
    James E Frampton
    Wolters Kluwer Health Adis, Auckland, New Zealand
    CNS Drugs 21:521-4. 2007
  30. doi Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects
    Kelly E Lyons
    University of Kansas Medical Center, Kansas City, KS 66160, USA
    Clin Neuropharmacol 33:5-10. 2010
    To determine whether adding orally disintegrating selegiline (ODS) while decreasing dopamine agonist (DA) dosages would reduce DA-related adverse effects (AEs) of excessive daytime sleepiness (EDS), pedal edema, hallucinations, and ..
  31. ncbi Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
    J Clin Psychopharmacol 26:579-86. 2006
    The selegiline transdermal system (STS) is a monoamine oxidase inhibitor (MAOI) with unique pharmacokinetic and pharmacodynamic properties that was developed to overcome limitations of orally administered MAOIs, particularly dietary ..
  32. ncbi A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition
    A Clarke
    Scherer DDS, Swindon, United Kingdom
    J Neural Transm 110:1257-71. 2003
    Three studies were performed using a fast dissolving formulation of selegiline hydrochloride designed for buccal absorption "Zydis Selegiline". The aim of the first study was to compare the therapeutic efficacy of Zydis Selegiline (1...
  33. ncbi Low dose (-)deprenyl is cytoprotective: it maintains mitochondrial membrane potential and eliminates oxygen radicals
    L Simon
    National Institute of Psychiatry and Neurology, National Stroke Center, Department of Vascular Neurology, Semmelweis University, Budapest H 1021 Hungary
    Life Sci 78:225-31. 2005
    ....
  34. ncbi Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl]
    Sevil Yasar
    Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    J Pharmacol Exp Ther 317:387-94. 2006
    l-Deprenyl [selegiline, (R)-(-)-deprenyl] is a selective inhibitor of monoamine oxidase B (MAO-B) used in the treatment of Parkinson's disease and proposed as an antidepressant and an aid for cigarette-smoking cessation and treatment of ..
  35. doi Optimization and validation of a dissolution test for selegiline hydrochloride tablets by a novel rapid HPLC assay using a monolithic stationary phase
    Paraskevas D Tzanavaras
    Laboratory of Analytical Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, GR 54124 Thessaloniki, Greece
    J Pharm Biomed Anal 46:670-5. 2008
    The present study reports the optimization and validation of a dissolution test for selegiline.HCl tablets using a new high-performance liquid chromatographic (HPLC) method...
  36. ncbi Orally disintegrating selegiline for the treatment of Parkinson's disease
    Matthias Lohle
    Technische Universitat Dresden, Department of Neurology, Fetscherstrasse 74, 01307 Dresden, Germany
    Expert Opin Pharmacother 9:2881-91. 2008
    The selective monoamine oxidase type B inhibitor selegiline is commonly administered as medical treatment to patients suffering from Parkinson's disease...
  37. ncbi Selegiline potentiates the effects of EGb 761 in response to ischemic brain injury
    Y S Kwon
    Neurotoxicology Program, College of Pharmacy, Korea Institute of Drug Abuse, Kangwon National University, Chunchon 200 701, South Korea
    Neurochem Int 45:157-70. 2004
    We evaluated whether combined treatment with selegiline, a selective MAO-B inhibitor, and EGb 761, a standard extract of Ginkgo biloba, has synergistic effects against ischemic reperfusion injury (IRI) in gerbils...
  38. ncbi Neuroprotective actions of Selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons
    Sushil K Sharma
    Department of Pharmacology, Physiology, and Therapeutics, University of North Dakota, School of Medicine and Health Sciences, Grand Forks, North Dakota, USA
    J Neurocytol 32:329-43. 2003
    ..4-phenyl, Pyridinium ion (MPP(+)) in SK-N-SH neurons and have evaluated the neuroprotective potential of Selegiline with a primary objective to explore its mechanism(s) of neuroprotection...
  39. ncbi (-)-D-Deprenyl attenuates apoptosis in experimental brain ischaemia
    L Simon
    National Institute of Psychiatry and Neurology, National Stroke Center, , H-1021, Budapest, Hungary
    Eur J Pharmacol 430:235-41. 2001
    ..D-Deprenyl treatment increased the number of GAP-43-positive cells. We conclude that (-)-D-deprenyl reduced the number of affected cells and induced neuronal plasticity...
  40. ncbi Increased cell-cell adhesion, a novel effect of R-(-)-deprenyl
    V Jenei
    Institute of Biomolecular Chemistry, Chemical Research Center, Hungarian Academy of Sciences, Budapest, Hungary
    J Neural Transm 112:1433-45. 2005
    ..The effect of R-(-)-deprenyl was not reversible during a 24-hour recovery period. In summary, we described a new, MAO-B independent effect of R-(-)-deprenyl on cell-cell adhesion which can contribute to its neuroprotective function...
  41. ncbi Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline
    A Kupsch
    Department of Neurology, Klinikum Grosshadern, Ludwig Maximilians University, and Institute of Physiology, Munchen, Federal Republic of Germany
    J Neural Transm 108:985-1009. 2001
    ..B (MAO-B) has been reported to be implicated in both MPTP-induced parkinsonism and Parkinson's disease, since selegiline (L-deprenyl), an irreversible MAO-B inhibitor, prevents MPTP-induced neurotoxicity in numerous species including ..
  42. ncbi Effects of selegiline on antioxidant systems in the nigrostriatum in rat
    K Takahata
    Research Institute, Fujimoto Pharmaceutical Corporation, Osaka, Japan
    J Neural Transm 113:151-8. 2006
    b>Selegiline, a therapeutic agent of Parkinson's disease, is known to have neuroprotective properties that may involve its regulatory effects on antioxidant enzymes...
  43. ncbi Selegiline in the management of apathy following traumatic brain injury
    Gil Newburn
    Rotorua Rehabilitation Clinic, Rotorua, New Zealand
    Brain Inj 19:149-54. 2005
    To provide a brief review of apathy following traumatic brain injury (TBI) and describe the use of selegiline in a group of patients with this symptom.
  44. ncbi The multiple actions of selegiline
    Manuchair Ebadi
    Department of Pharmacology, Physiology, and Therapeutics, University of North Dakota, School of Medicine and Health Sciences, P O Box 9037, 501 North Columbia Road, Grand Forks, ND 58203, USA
    Proc West Pharmacol Soc 45:39-41. 2002
  45. pmc Selegiline and oxidative stress in HIV-associated cognitive impairment
    G Schifitto
    University of Rochester, NY, USA
    Neurology 73:1975-81. 2009
    To assess the effectiveness of the selegiline transdermal system (STS) in reversing HIV-induced metabolic brain injury (as measured by proton magnetic resonance spectroscopy [MRS]) and in decreasing oxidative stress, measured by CSF ..
  46. ncbi Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline
    Orit Bar Am
    Eve Topf and US National Parkinson Foundation Center of Excellence for Neurodegenerative Diseases Research, Technion Faculty of Medicine, Efron St PO Box 9697, Haifa 31096, Israel
    Neurosci Lett 355:169-72. 2004
    The anti-Parkinson selective irreversible monoamine oxidase B inhibitor drugs, rasagiline and selegiline, have been shown to possess neuroprotective activities in cell culture and in vivo models...
  47. ncbi Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort
    C Marras
    Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada M5T 2S8
    Neurology 64:87-93. 2005
    ..To investigate predictors of survival in Parkinson disease (PD)...
  48. ncbi Amphetamine-induced locomotor activity is reduced in mice following MPTP treatment but not following selegiline/MPTP treatment
    Brian D West
    Neuroscience Drug Discovery, Merck Research Laboratories, P O Box 4, WP44E 200, West Point, PA 19486, USA
    Pharmacol Biochem Behav 84:158-61. 2006
    ..Further, the potential for use of this endpoint to evaluate putative therapeutics is exemplified by the amelioration of these effects following pre-treatment with the MAO-B inhibitor selegiline.
  49. ncbi Selegiline long-term effects on brain acetylcholinesterase, (Na+,K+)-ATPase activities, antioxidant status and learning performance of aged rats
    Haris Carageorgiou
    Department of Experimental Pharmacology, Medical School, University of Athens, Athens, Greece
    Pharmacol Res 48:245-51. 2003
    The aim of this study was to investigate the effects of selegiline ((-)deprenyl), an irreversible inhibitor of monoaminoxidase-B (MAO-B): (a) on brain acetylcholinesterase (AChE), (Na(+),K(+))-ATPase and Mg(2+)-ATPase activities; (b) ..
  50. ncbi Selegiline potentiates cocaine-induced increases in rodent nucleus accumbens dopamine
    Wynne K Schiffer
    Department of Neurobiology and Behavior, Stony Brook University, Stony Brook, New York 11794, USA
    Synapse 48:35-8. 2003
    b>Selegiline has been proposed as a treatment for cocaine addiction and studies in humans suggest that it attenuates cocaine's reinforcing effects...
  51. ncbi Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial
    Alan D Feiger
    Department of Psychiatry, University of Colorado School of Medicine, Denver, CO, USA
    J Clin Psychiatry 67:1354-61. 2006
    This study investigated the efficacy, safety, and tolerability of the selegiline transdermal system (STS) administered in a dose range of 6 mg/24 hours to 12 mg/24 hours for treating major depressive disorder (MDD).
  52. ncbi A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, USA
    J Clin Psychiatry 64:208-14. 2003
    The monoamine oxidase (MAO) inhibitor selegiline has demonstrated antidepressant efficacy superior to placebo...
  53. ncbi Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues
    Michael Mawhinney
    Department of Pharmacology, West Virginia University School of Medicine, Morgantown, WV 26506, USA
    J Pharm Pharmacol 55:27-34. 2003
    b>Selegiline has been formulated in an acrylic polymer adhesive mixture to be employed as a constant release topical patch for daily transdermal administration...
  54. ncbi Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems
    Jarmo S Salonen
    Orion Pharma Preclinical and Clinical R and D, Turku, Finland
    Drug Metab Dispos 31:1093-102. 2003
    b>Selegiline was used as a model compound in a project aimed at comparing, evaluating, and integrating different in vitro approaches for the prediction of cytochrome p450 (p450)-catalyzed hepatic drug metabolism in humans (EUROCYP)...
  55. ncbi Effects of selegiline alone or with donepezil on memory impairment in rats
    Kazue Takahata
    Research Institute, Fujimoto Pharmaceutical Corporation, 1 3 40 Nishiotsuka, Matsubara, Osaka 580 0011, Japan
    Eur J Pharmacol 518:140-4. 2005
    b>Selegiline, a monoamine oxidase-B inhibitor, is reported to improve memory and learning in dementia of Alzheimer's type. However, only a few studies have reported its use in animal models...
  56. ncbi Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline
    Keiko Kamakura
    Third Department of Internal Medicine, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama 359 8513, Japan
    Parkinsonism Relat Disord 10:235-42. 2004
    b>Selegiline protects nigral dopaminergic neurons and is recommended for the treatment of patients in the early stage of Parkinson's disease (PD)...
  57. ncbi Antidepressant-like effects of selegiline in the forced swim test
    Seiichiro Shimazu
    Research Institute, Fujimoto Pharmaceutical Corporation, 1 3 40 Nishiotsuka, Matsubara, Osaka 580 0011, Japan
    Eur Neuropsychopharmacol 15:563-71. 2005
    Although selegiline, a monoamine oxidase (MAO)-B inhibitor, is reported to exert antidepressant effects in depressant patients, evidence in rodents for effects of selegiline is quite limited...
  58. ncbi A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline
    Thomas F Newton
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at the University of California at Los Angeles, USA
    Pharmacol Biochem Behav 82:704-11. 2005
    b>Selegiline (L-deprenyl) is a selective irreversible monoamine oxidase B inhibitor shown to be effective in the treatment of Parkinson's and Alzheimer's diseases...
  59. ncbi Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus
    N Hamaue
    The Research Institute of Personalized Health Sciences, Health Sciences University of Hokkaido, 061 0293 Ishikari Tobetsu, Japan
    Neurotoxicology 25:205-13. 2004
    ..b>Selegiline [(-)-deprenil] was developed as a MAO-B inhibitor more than 30 years ago and widely used in the treatment of ..
  60. ncbi Selegiline slows the progression of the symptoms of Parkinson disease
    S Palhagen
    Department of Neurology, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    Neurology 66:1200-6. 2006
    To study the long-term effects of selegiline in monotherapy and in combination with levodopa in the early phase of Parkinson disease (PD).
  61. ncbi A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition
    A Clarke
    Scherer DDS, Swindon, United Kingdom
    J Neural Transm 110:1241-55. 2003
    ..studies were conducted in healthy volunteers to compare the pharmacokinetic and pharmacodynamic profiles of selegiline hydrochloride in a new formulation designed for buccal absorption "Zydis Selegiline" (1...
  62. ncbi Transdermal selegiline: targeted effects on monoamine oxidases in the brain
    Lynn Wecker
    Department of Pharmacology and Therapeutics, University of South Florida College of Medicine, Tampa, Florida 33612 4799, USA
    Biol Psychiatry 54:1099-104. 2003
    ..These studies determined whether the transdermal administration of selegiline has differential effects on MAOs in brain versus the gastrointestinal system.
  63. ncbi Transdermal selegiline and intravenous cocaine: safety and interactions
    Elisabeth J Houtsmuller
    Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Bayview Medical Center, 5510 Nathan Shock Drive, Baltimore, MD 21224 6823, USA
    Psychopharmacology (Berl) 172:31-40. 2004
    ..b>Selegiline, a selective monoamine oxidase B inhibitor, indirectly modulates dopamine levels, and research suggests ..
  64. ncbi A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation
    R Biberman
    Division of Health, Maccabi Health Care Services, Sackler Medical Faculty, Tel Aviv University, Israel
    Addiction 98:1403-7. 2003
    To compare the effect of oral selegiline plus nicotine patch with placebo plus nicotine patch on smoking cessation rates.
  65. ncbi Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence
    Ahmed Elkashef
    National Institute on Drug Abuse NIDA, Division of Pharmacotherapies and Medical Consequences of Drug Abuse DPMCDA, MSC 9551 Bethesda, MD 20892, USA
    Drug Alcohol Depend 85:191-7. 2006
    Cocaine dependence is a major public health problem for which there is no FDA-approved pharmacological treatment. Selegiline is an irreversible selective inhibitor of monoamine oxidase type B (MAO-B) which may affect cocaine addiction ..
  66. pmc Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline
    Zaid A Abassi
    Department of Physiology and Biophysics, Technion Rappaport Faculty of Medicine and Rappaport Family Institute for Research in the Medical Sciences, Technion, Haifa, Israel
    Br J Pharmacol 143:371-8. 2004
    b>Selegiline is used for treating Parkinson's disease...
  67. ncbi A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation
    Tony P George
    Program for Research in Smokers with Mental Illness PRISM, New Haven, Connecticut 06519, USA
    Biol Psychiatry 53:136-43. 2003
    ..mechanisms appear to be involved in nicotine dependence, we studied the safety and efficacy of the monoamine oxidase B inhibitor selegiline hydrochloride compared with placebo for smoking cessation in nicotine-dependent cigarette smokers.
  68. ncbi A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment
    G Schifitto
    Department of Neurology, Movement and Inherited Neurologic Disorders, Clinical Trials Coordination Center, 1351 Mount Hope Avenue, Suite 223, Rochester, NY 14620, USA
    Neurology 69:1314-21. 2007
    ..b>Selegiline is an MAO-B inhibitor with antioxidant and neurotrophic properties...
  69. ncbi Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects
    Albert J Azzaro
    Somerset Pharmaceuticals, Inc, Tampa, Florida, USA
    J Clin Pharmacol 46:933-44. 2006
    The oral tyramine pressor test was administered to healthy males during treatment with a selegiline transdermal system (STS; 6 mg/24 h)...
  70. ncbi The influence of metabolism on the MAO-B inhibitory potency of selegiline
    D Haberle
    Department of Pharmacodynamics Semmelweis University, H 1445 Budapest, Hungary
    Curr Med Chem 9:47-51. 2002
    Deprenyl (selegiline), a propargylamine derivative of methylamphetamine, is a potent, irreversible inhibitor of monoamine-oxidase type B (MAO-B). The MAO-B inhibitory effects of various doses (0.1-0.25-0...
  71. ncbi The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials
    G K Wilcock
    Department of Care of the Elderly, University of Bristol, UK
    Int J Geriatr Psychiatry 17:175-83. 2002
    To evaluate the effect of selegiline in the treatment of patients with Alzheimer's disease, in terms of cognitive performance, functional ability, emotional state (including behaviour and mood) and global response...
  72. ncbi Clomipramine and selegiline: do they influence impulse control?
    B Bert
    Institute of Pharmacology and Toxicology, School of Veterinary Medicine, Freie Universitat Berlin, Berlin, Germany
    J Vet Pharmacol Ther 29:41-7. 2006
    ..The reduction of these undesirable actions is the focus of behaviour therapy. Clomipramine and selegiline have been approved for the treatment of separation anxiety in dogs, but there are anecdotal reports that they ..
  73. ncbi Chronic daily administration of selegiline and EGb 761 increases brain's resistance to ischemia in mice
    I Unal
    Department of Neurology, Faculty of Medicine and Institute of Neurological Sciences and Psychiatry, Hacettepe University, 06100, Ankara, Turkey
    Brain Res 917:174-81. 2001
    ..Acute administration of selegiline and EGb 761 have been shown to have anti-apoptotic and neuroprotective effects in experimental ischemia...
  74. ncbi Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study
    A Negrotti
    Istituto di Neurologia, , Italy
    J Neural Transm 108:215-9. 2001
    Following a two-months of placebo-controlled withdrawal, the MAO-B inhibitor selegiline was found to maintain a long term significant mild to moderate symptomatic effect on bradykinesia and tremor at rest in nine patients with Parkinson's ..
  75. ncbi Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications
    Albert J Azzaro
    Chief Scientific Officer, Somerset Pharmaceuticals, Inc, Rocky Point Center, 3030 North Rocky Point Drive, Suite 250, Tampa, FL 33607, USA
    J Clin Pharmacol 47:146-58. 2007
    b>Selegiline transdermal system (STS) is a recently approved monoamine oxidase inhibitor antidepressant...
  76. ncbi Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes
    P Taavitsainen
    Department of Pharmacology and Toxicology, University of Oulu, Finland
    Pharmacol Toxicol 86:215-21. 2000
    Although being a drug therapeutically used for a long time, the enzymatic metabolism of selegiline has not been adequately studied...
  77. ncbi Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study
    N Sacktor
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Neurology 54:233-5. 2000
    ..a pilot randomized, double-blind, placebo-controlled clinical trial of the transdermal administration of selegiline in HIV+ patients to obtain preliminary data to assess its safety, tolerability, and impact on HIV-associated ..
  78. ncbi Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice
    Eric C K Siu
    Department of Pharmacology, University of Toronto, 1 King s College Circle, Room 4326, Toronto, Ontario, Canada
    J Pharmacol Exp Ther 324:992-9. 2008
    b>Selegiline (l-deprenyl) is in clinical treatment trials as a potential smoking cessation drug. We investigated the affect of selegiline and its metabolites on nicotine metabolism...
  79. ncbi Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation
    Rita Moretti
    Int J Geriatr Psychiatry 17:391-2. 2002
  80. ncbi Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers
    Albert J Azzaro
    Somerset Pharmaceuticals, Inc
    J Clin Pharmacol 47:978-90. 2007
    b>Selegiline transdermal system is a recently approved monoamine oxidase inhibitor antidepressant...
  81. pmc Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis
    Shawna Tazik
    Division of Neurobiology and Behavioral Research, Department of Psychiatry and Human Behavior G 109, University of Mississippi Medical Center, 2500N State Street, Jackson, MS 39216, USA
    Neurotox Res 15:284-90. 2009
    ..In this study, we have compared the ability of rasagiline (Azilect) and its main metabolite, R-aminoindan with selegiline (Deprenyl) in prevention of dexamethasone-induced brain cell death employing human neuroblastoma SH-SY5Y cells ..
  82. ncbi The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30
    Moussa B H Youdim
    Eve Topf Centres of Excellence for Neurodegenerative Diseases Research, Technion Rappaport Family Faculty of Medicine and Department of Pharmacology, Haifa, Israel
    Curr Alzheimer Res 3:541-50. 2006
    ..has its origin in the anti Parkinson action of the selective monoamine oxidase (MAO) B inhibitor, l-deprenyl (selegiline ), a failed anti depressant in 1975...
  83. ncbi Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients
    J Alexander Bodkin
    McLean Hospital, 115 Mill St Belmont, MA 02478, USA
    Am J Psychiatry 159:1869-75. 2002
    The authors investigated the efficacy and safety of transdermal selegiline in adult outpatients with major depressive disorder.
  84. ncbi Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour
    Lawrence F Blob
    Somerset Pharmaceuticals, Tampa, FL 33607, USA
    CNS Spectr 12:25-34. 2007
    ..A selegiline transdermal system (STS) was developed to provide antidepressant concentrations of selegiline in the brain, ..
  85. ncbi Urinary excretion of selegiline N-oxide, a new indicator for selegiline administration in man
    M Katagi
    Forensic Science Laboratory, Osaka Prefectural Police HQ, 1 3 18, Hommachi, Chuoku, Osaka 541 0053, Japan
    Xenobiotica 32:823-31. 2002
    1. The metabolism of selegiline (SG) has been studied by investigating the time-course of urinary excretion of SG and its metabolites using high-performance liquid chromatography-electrospray ionization mass spectrometry (LC-ESI MS) in ..
  86. pmc Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group
    V Filip
    Department of Psychiatry, Comenius University, Bratislava, Slovak Republic
    J Psychiatry Neurosci 24:234-43. 1999
    To evaluate the efficacy and adverse effects of the type B monoamine oxidase inhibitor selegiline (also known as I-deprenyl) in the treatment of Alzheimer's disease.
  87. ncbi CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes
    M Hidestrand
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden
    Drug Metab Dispos 29:1480-4. 2001
    In view of conflicting data in the literature regarding the enzyme(s) responsible for metabolism of selegiline, a drug used in the treatment of Parkinson's disease, investigations were carried out in vitro using the human cytochrome P450 ..
  88. ncbi Selegiline completely restores choline acetyltransferase activity deficits in simian immunodeficiency infection
    E Koutsilieri
    Clinical Neurochemistry, Department of Psychiatry, University of Wurzburg, Fuchsleinstr 15, 97080, Wurzburg, Germany
    Eur J Pharmacol 411:R1-R2. 2001
    ..We report now that selegiline, completely restores the reduced choline acetyltransferase activity which encourages for a meaningful anti-..
  89. ncbi Selegiline in narcolepsy
    S E Roselaar
    University Department of Neurology, King's College School of Medicine, London, England
    Sleep 10:491-5. 1987
    We examined the effect of the specific monoamine oxidase-B (MAO-B) inhibitor selegiline (deprenyl, Eldepryl), 20-30 mg p.o. daily, in 21 subjects with the narcoleptic syndrome for 4 weeks...
  90. ncbi Effects of (-)deprenyl (selegiline) on acetylcholinesterase and Na(+),K(+)-ATPase activities in adult rat whole brain
    Charalambos Antoniades
    Department of Experimental Physiology, Medical School, University of Athens, P O Box 65257, GR 154 01 Athens, Greece
    Pharmacol Res 46:165-9. 2002
    ..We conclude that (-)deprenyl is an indirect AChE inhibitor and Na(+),K(+)-ATPase stimulator in the rat brain (in vitro)...
  91. ncbi Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
    Ira Shoulson
    University of Rochester Medical Center, Rochester, NY 14620, USA
    Ann Neurol 51:604-12. 2002
    Deprenyl (selegiline) delays the need for levodopa therapy in patients with early Parkinson's disease, but the long-term benefits of this treatment remain unclear...
  92. ncbi Toxicokinetic evaluation of a selegiline transdermal system in the dog
    J S Barrett
    Somerset Pharmaceuticals, Tampa, FL, USA
    Biopharm Drug Dispos 18:165-84. 1997
    The toxicology and toxicokinetics of a selegiline transdermal system (STS) were evaluated in a 3 month dog study of daily 24 h applications of placebo 4, 8, or 12 STSs in 32 male and 32 female beagle dogs...
  93. ncbi Selegiline's neuroprotective capacity revisited
    P Riederer
    Clinical Neurochemistry, Clinic and Policlinic for Psychiatry and Psychotherapy, University of Wuerzburg, Germany
    J Neural Transm 110:1273-8. 2003
  94. ncbi Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
    Christopher G Goetz
    Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center, Chicago, Illinois 60612, USA
    Mov Disord 20:523-39. 2005
    ..b>Selegiline was reassigned as Non-efficacious for the prevention of dyskinesias. Other designations did not change...
  95. ncbi Other pharmacological treatments for motor complications and dyskinesias
    Cheryl Waters
    Division of Movement Disorders, Department of Neurology, Columbia University, 710 West 168th Street, New York, NY 10032, USA
    Mov Disord 20:S38-44. 2005
    ..Patients may also suffer from dyskinesias. Dyskinesias can be treated with small doses of liquefied levodopa-carbidopa, amantadine, and clozapine, an atypical neuroleptic...
  96. ncbi [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508]
    Ildiko Miklya
    Semmelweis Egyetem, AOK, Farmakológiai és Farmakoterápiás Intézet, Budapest
    Neuropsychopharmacol Hung 10:15-22. 2008
    ..Thus, rasagiline can not be a substitute for (-)-deprenyl in therapy...
  97. ncbi Reexamination of the TEMPO Study
    Clifford W Shults
    Arch Neurol 62:1320; author reply 1321. 2005
  98. ncbi Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells
    Thomas Muller
    Department of Neurology, St Josef Hospital, University of Bochum, Gudrunstr 56, 44791 Bochum, Germany
    Neurol Res 30:417-9. 2008
    Long-term administration of the monoamine oxidase (MAO)-B inhibitor selegiline may reduce neuronal death based on preclinical findings and reduce progression of chronic neurodegeneration due to outcomes of long-term clinical trials in ..
  99. ncbi Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice
    Atsushi Mori
    Research Unit for Neurological Diseases, Second Institute of New Drug Discovery, Otsuka Pharmaceutical Co, Ltd, Tokushima City, Tokushima 771 0192, Japan
    Neurosci Res 51:265-74. 2005
    ..We concluded that the increase in immobility time in the TST was induced by the nigrostriatal dopaminergic degeneration and was thought to be a consequence of motor dysfunction in this mouse model of PD...
  100. ncbi Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease
    Jack J Chen
    Movement Disorders Center, Loma Linda University, Loma Linda, CA, USA
    J Clin Pharmacol 45:878-94. 2005
    ..Rasagiline completely and selectively inhibits MAO-B with a potency 5 to 10 times greater than selegiline. Unlike the prototype propargylamine selegiline, which is metabolized to amphetamine derivatives, rasagiline is ..
  101. ncbi The effect of deprenyl washout in patients with long-standing Parkinson's disease
    R Djaldetti
    Department of Neurology and the Felsenstein Research Center, Rabin Medical Center, Beilinson Campus, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    J Neural Transm 109:797-803. 2002
    ..Attempts to discontinue treatment with deprenyl may aggravate disease symptoms...

Research Grants76

  1. CARDIOVASCULAR DISEASE PREVENTION TRAINING PROGRAM
    Stephen Fortmann; Fiscal Year: 2007
    ..and improving quality of life in persons over 65, behavioral maintenance treatment in smoking cessation, selegiline for smoking cessation, retail tobacco marketing effects on adolescent smoking initiation, pro- and anti-smoking ..
  2. RADIOTRACER RANDD IN NUCLEAR MEDICINE AND NEUROSCIENCES
    Joanna Fowler; Fiscal Year: 1999
    ....
  3. RADIOTRACER RANDD IN NUCLEAR MEDICINE AND NEUROSCIENCES
    Joanna Fowler; Fiscal Year: 2000
    ....
  4. DOPAMINERGIC AGENTS ON ACUTE RESPONSES TO SMOKING
    Lisa Brauer; Fiscal Year: 2001
    Purpose: The goal of this study is to to explore the effects of the MAO-B inhibitor, selegiline, on smoking cessation attempts...
  5. DOPAMINERGIC AGENTS ON ACUTE RESPONSES TO SMOKING
    Lisa Brauer; Fiscal Year: 1999
    Purpose: The goal of this study is to to explore the effects of the MAO-B inhibitor, selegiline, on smoking cessation attempts...
  6. Levodopa Pharmokinetic Optimization by Metal Coordination
    Thomas Piccariello; Fiscal Year: 2009
    ..While drugs like entacapone, carbidopa and selegiline help to inhibit metabolism, extending the absorption phase is limited by a dependence on active transport ..
  7. RADIOTRACER R & D IN NUCLEAR MEDICINE AND NEUROSCIENCES
    Joanna Fowler; Fiscal Year: 2001
    ....
  8. RADIOTRACER R & D IN NUCLEAR MEDICINE AND NEUROSCIENCES
    Joanna Fowler; Fiscal Year: 2003
    ....
  9. PILOT STUDY--SELEGILINE FOR SMOKING CESSATION
    Tony George; Fiscal Year: 2001
    We are proposing a placebo-controlled pilot study of selegiline versus placebo for nicotine dependent smokers (N=30) with depressive symptoms...
  10. PILOT STUDY--SELEGILINE FOR SMOKING CESSATION
    Tony George; Fiscal Year: 2002
    We are proposing a placebo-controlled pilot study of selegiline versus placebo for nicotine dependent smokers (N=30) with depressive symptoms...
  11. PILOT STUDY--SELEGILINE FOR SMOKING CESSATION
    Tony George; Fiscal Year: 2000
    We are proposing a placebo-controlled pilot study of selegiline versus placebo for nicotine dependent smokers (N=30) with depressive symptoms...
  12. PILOT STUDY--SELEGILINE FOR SMOKING CESSATION
    Tony George; Fiscal Year: 1999
    We are proposing a placebo-controlled pilot study of selegiline versus placebo for nicotine dependent smokers (N=30) with depressive symptoms...
  13. PARKINSON DISEASE NEUROPROTECTION CLINICAL TRIAL CENTER
    Bala Manyam; Fiscal Year: 2002
    ..disease, not yet requiring symptomatic treatment and unexposed to prior treatment with levodopa/dopamine agonist/selegiline (within four months). 3)...
  14. PARKINSON DISEASE NEUROPROTECTION CLINICAL TRIAL CENTER
    Bala Manyam; Fiscal Year: 2003
    ..disease, not yet requiring symptomatic treatment and unexposed to prior treatment with levodopa/dopamine agonist/selegiline (within four months). 3)...
  15. PARKINSON DISEASE NEUROPROTECTION CLINICAL TRIAL CENTER
    Bala Manyam; Fiscal Year: 2005
    ..disease, not yet requiring symptomatic treatment and unexposed to prior treatment with levodopa/dopamine agonist/selegiline (within four months). 3)...
  16. Selegiline for Smoking Cessation
    MARC POTENZA; Fiscal Year: 2007
    ..In support of this hypothesis, in preliminary studies, we have shown that the selective MAO-B inhibitor selegiline hydrochloride (10 mg/day) significantly increases smoking abstinence rates compared to placebo...
  17. Selegiline for Smoking Cessation
    Tony George; Fiscal Year: 2004
    ..In support of this hypothesis, in preliminary studies, we have shown that the selective MAO-B inhibitor selegiline hydrochloride (10 mg/day) significantly increases smoking abstinence rates compared to placebo...
  18. Selegiline for Smoking Cessation
    Tony George; Fiscal Year: 2006
    ..In support of this hypothesis, in preliminary studies, we have shown that the selective MAO-B inhibitor selegiline hydrochloride (10 mg/day) significantly increases smoking abstinence rates compared to placebo...
  19. Selegiline for Smoking Cessation
    Tony George; Fiscal Year: 2005
    ..In support of this hypothesis, in preliminary studies, we have shown that the selective MAO-B inhibitor selegiline hydrochloride (10 mg/day) significantly increases smoking abstinence rates compared to placebo...
  20. UBIQUINONE AND MITOCHONDRIAL OXIDATIVE DISORDERS OF AGIN
    Manuchair Ebadi; Fiscal Year: 2002
    ..pathways, G actin, and neurofilaments in neurons; C) to test the effects of neuroprotectants such as selegiline on the striatal-, hippocampal-, and cortical levels of coenzyme Q10; D) to explore the antioxidant coregulation ..
  21. UBIQUINONE AND MITOCHONDRIAL OXIDATIVE DISORDERS OF AGIN
    Manuchair Ebadi; Fiscal Year: 2001
    ..pathways, G actin, and neurofilaments in neurons; C) to test the effects of neuroprotectants such as selegiline on the striatal-, hippocampal-, and cortical levels of coenzyme Q10; D) to explore the antioxidant coregulation ..
  22. UBIQUINONE AND MITOCHONDRIAL OXIDATIVE DISORDERS OF AGIN
    Manuchair Ebadi; Fiscal Year: 1999
    ..pathways, G actin, and neurofilaments in neurons; C) to test the effects of neuroprotectants such as selegiline on the striatal-, hippocampal-, and cortical levels of coenzyme Q10; D) to explore the antioxidant coregulation ..
  23. UBIQUINONE AND MITOCHONDRIAL OXIDATIVE DISORDERS OF AGIN
    Manuchair Ebadi; Fiscal Year: 2000
    ..pathways, G actin, and neurofilaments in neurons; C) to test the effects of neuroprotectants such as selegiline on the striatal-, hippocampal-, and cortical levels of coenzyme Q10; D) to explore the antioxidant coregulation ..
  24. VITAMIN E AND ARICEPT TO DELAY ALZHEIMER'S DISEASE
    Mary Sano; Fiscal Year: 2000
    ..stress mechanisms in disease pathogenesis was also suggested by a recent clinical trial of vitamin E and selegiline in subjects with moderate AD. This clinical trial indicates that treatment with vitamin E(2,000I.U...
  25. Selegiline for Treatment of Cannabis Dependence
    BRENT MOORE; Fiscal Year: 2005
    ..b>Selegiline, a monoamine oxidase-B inhibitor, increases dopamine activity in mesolimbic and other brain regions involved in ..
  26. Selegiline for Treatment of Cannabis Dependence
    BRENT MOORE; Fiscal Year: 2004
    ..b>Selegiline, a monoamine oxidase-B inhibitor, increases dopamine activity in mesolimbic and other brain regions involved in ..
  27. Selegiline, Oxidative Stress and MRS in HIV Dementia
    Giovanni Schifitto; Fiscal Year: 2001
    ..mitochondrial membrane potential abnormalities can be reversed by drugs with antioxidant properties including selegiline (L-deprenyl)...
  28. Selegiline, Oxidative Stress and MRS in HIV Dementia
    Giovanni Schifitto; Fiscal Year: 2002
    ..mitochondrial membrane potential abnormalities can be reversed by drugs with antioxidant properties including selegiline (L-deprenyl)...
  29. NEUROLOGIC AIDS RESEARCH CONSORTIUM
    David Clifford; Fiscal Year: 2005
    ..Complete and analyze A5090 testing the safety and efficacy of transdermal selegiline for HIV- associated motor cognitive disorder; 2...
  30. NEUROLOGIC AIDS RESEARCH CONSORTIUM
    David Clifford; Fiscal Year: 2007
    ..Complete and analyze A5090 testing the safety and efficacy of transdermal selegiline for HIV- associated motor cognitive disorder; 2...
  31. NEUROLOGIC AIDS RESEARCH CONSORTIUM
    David Clifford; Fiscal Year: 2004
    ..Complete and analyze A5090 testing the safety and efficacy of transdermal selegiline for HIV- associated motor cognitive disorder; 2...
  32. NEUROLOGIC AIDS RESEARCH CONSORTIUM
    David Clifford; Fiscal Year: 2003
    ..Complete and analyze A5090 testing the safety and efficacy of transdermal selegiline for HIV- associated motor cognitive disorder; 2...
  33. EFFECTS OF NICOTINE ON ATTENTIONAL FUNCTIONING IN ALZHEIMER'S AND PARKINSON'S
    Paul Newhouse; Fiscal Year: 1999
    ..This was the model used in the pivotal selegiline trial (DATTOP Study) that established that selegiline appeared to delay the time to onset of severe enough ..
  34. Parkinson's Disease Neuroprotection Clinical Trial
    Burton L Scott; Fiscal Year: 2010
    ..At this time, only selegiline (Eldrepyl), a selective monoamine oxidase-B (MAO-B) inhibitor has been approved by the US Food &Drug ..
  35. Parkinson's Disease Neuroprotection Clinical Trial
    Burton L Scott; Fiscal Year: 2011
    ..At this time, only selegiline (Eldrepyl), a selective monoamine oxidase-B (MAO-B) inhibitor has been approved by the US Food &Drug ..
  36. Parkinson's Disease Neuroprotection Clinical Trial
    Burton Scott; Fiscal Year: 2003
    ..At this time, only selegiline (Eldrepyl), a selective monoamine oxidase-B (MAO-B) inhibitor has been approved by the US Food & Drug ..
  37. Parkinson's Disease Neuroprotection Clinical Trial
    Burton Scott; Fiscal Year: 2009
    ..At this time, only selegiline (Eldrepyl), a selective monoamine oxidase-B (MAO-B) inhibitor has been approved by the US Food &Drug ..
  38. Parkinson's Disease Neuroprotection Clinical Trial
    Burton Scott; Fiscal Year: 2006
    ..At this time, only selegiline (Eldrepyl), a selective monoamine oxidase-B (MAO-B) inhibitor has been approved by the US Food & Drug ..
  39. Parkinson's Disease Neuroprotection Clinical Trial
    Burton Scott; Fiscal Year: 2005
    ..At this time, only selegiline (Eldrepyl), a selective monoamine oxidase-B (MAO-B) inhibitor has been approved by the US Food & Drug ..
  40. Parkinson's Disease Neuroprotection Clinical Trial
    Burton L Scott; Fiscal Year: 2010
    ..At this time, only selegiline (Eldrepyl), a selective monoamine oxidase-B (MAO-B) inhibitor has been approved by the US Food &Drug ..
  41. Parkinson's Disease Neuroprotection Clinical Trial: Clinical Center
    Burton Scott; Fiscal Year: 2007
    ..At this time, only selegiline (Eldrepyl), a selective monoamine oxidase-B (MAO-B) inhibitor has been approved by the US Food & Drug ..
  42. Norepinephrine and Nerve Growth Factor in Heart Failure
    Chang Seng Liang; Fiscal Year: 2002
    ..Superoxide dismutase and selegiline, which have been shown to prevent cardiac sympathetic nerve abnormalities in heart failure, will be used to ..
  43. Norepinephrine and Nerve Growth Factor in Heart Failure
    Chang Seng Liang; Fiscal Year: 2004
    ..Superoxide dismutase and selegiline, which have been shown to prevent cardiac sympathetic nerve abnormalities in heart failure, will be used to ..
  44. Parkinson's Disease Neuroprotection Clinical Trial
    Burton Scott; Fiscal Year: 2002
    ..At this time, only selegiline (Eldrepyl), a selective monoamine oxidase-B (MAO-B) inhibitor has been approved by the US Food & Drug ..
  45. Pharmacokinetic interactions:selegiline and cocaine
    John Mendelson; Fiscal Year: 2000
    ..A recent cocaine treatment trial suggested the MAO-B inhibitor selegiline may be use-ful for treatment of cocaine dependence...
  46. Norepinephrine and Nerve Growth Factor in Heart Failure
    Chang Seng Liang; Fiscal Year: 2001
    ..Superoxide dismutase and selegiline, which have been shown to prevent cardiac sympathetic nerve abnormalities in heart failure, will be used to ..
  47. Norepinephrine and Nerve Growth Factor in Heart Failure
    Chang Seng Liang; Fiscal Year: 2003
    ..Superoxide dismutase and selegiline, which have been shown to prevent cardiac sympathetic nerve abnormalities in heart failure, will be used to ..
  48. Pharmacokinetic interactions:selegiline and cocaine
    John Mendelson; Fiscal Year: 2001
    ..A recent cocaine treatment trial suggested the MAO-B inhibitor selegiline may be use-ful for treatment of cocaine dependence...
  49. METABOLIC STUDIES IN DEMENTIA, AGING AND DEMYELINATION
    STUART SCHNECK; Fiscal Year: 1991
    ..pattern of AD and PD; 4) potential treatment for asymptomatic carriers of AD and PD if agents, such as selegiline and/or antioxidants in PD, can be shown to prevent or delay manifest disease; 5) expansion of the list of ..
  50. SAFETY/TOLERABILITY/EFFICACY OF SELEGILINE TRANSDERMAL SYSTEM IN AIDS DEMENTIA
    Ned Sacktor; Fiscal Year: 1999
    ..b>Selegiline, at very low dosages, has a trophic effect on injured neurons in vitro and vivo, and may prevent an increase in ..
  51. Selegiline Patch for Treatment of Nicotine Dependence
    Joel Killen; Fiscal Year: 2003
    ..Primary aim: To conduct the first randomized controlled trial of the efficacy of selegiline patch (STS) for the treatment of nicotine dependence...
  52. Selegiline Patch for Treatment of Nicotine Dependence
    Joel Killen; Fiscal Year: 2007
    ..Primary aim: To conduct the first randomized controlled trial of the efficacy of selegiline patch (STS) for the treatment of nicotine dependence...
  53. Selegiline Patch for Treatment of Nicotine Dependence
    Joel Killen; Fiscal Year: 2006
    ..Primary aim: To conduct the first randomized controlled trial of the efficacy of selegiline patch (STS) for the treatment of nicotine dependence...
  54. CARDIOVASCULAR DISEASE PREVENTION TRAINING PROGRAM
    Christopher Gardner; Fiscal Year: 2009
    ..and improving quality of life in persons over 65, behavioral maintenance treatment in smoking cessation, selegiline for smoking cessation, retail tobacco marketing effects on adolescent smoking initiation, pro- and anti-smoking ..
  55. CARDIOVASCULAR DISEASE PREVENTION TRAINING PROGRAM
    Christopher D Gardner; Fiscal Year: 2010
    ..and improving quality of life in persons over 65, behavioral maintenance treatment in smoking cessation, selegiline for smoking cessation, retail tobacco marketing effects on adolescent smoking initiation, pro- and anti-smoking ..
  56. CARDIOVASCULAR DISEASE PREVENTION TRAINING PROGRAM
    Stephen Fortmann; Fiscal Year: 2006
    ..and improving quality of life in persons over 65, behavioral maintenance treatment in smoking cessation, selegiline for smoking cessation, retail tobacco marketing effects on adolescent smoking initiation, pro- and anti-smoking ..
  57. SAFETY/TOLERABILITY/EFFICACY OF SELEGILINE TRANSDERMAL SYSTEM IN AIDS DEMENTIA
    Ned Sacktor; Fiscal Year: 1999
    ..b>Selegiline is an approved and marketed selective monoamine oxidase type B inhibitor...
  58. SAFETY/TOLERABILITY/EFFICACY OF SELEGILINE TRANSDERMAL SYSTEM IN AIDS DEMENTIA
    Ned Sacktor; Fiscal Year: 1999
    ..b>Selegiline is an approved and marketed selective monoamine oxidase type B inhibitor...
  59. SAFETY/TOLERABILITY/EFFICACY OF SELEGILINE TRANSDERMAL SYSTEM IN AIDS DEMENTIA
    Ned Sacktor; Fiscal Year: 2000
    ..b>Selegiline is an approved and marketed selective monoamine oxidase type B inhibitor...
  60. SAFETY/TOLERABILITY/EFFICACY OF SELEGILINE TRANSDERMAL SYSTEM IN AIDS DEMENTIA
    Ned Sacktor; Fiscal Year: 2002
    ..b>Selegiline is an approved and marketed selective monoamine oxidase type B inhibitor...
  61. SAFETY/TOLERABILITY/EFFICACY OF SELEGILINE TRANSDERMAL SYSTEM IN AIDS DEMENTIA
    Ned Sacktor; Fiscal Year: 2001
    ..b>Selegiline is an approved and marketed selective monoamine oxidase type B inhibitor...
  62. MAINTAINING FUNCTIONS IN AGED COMMUNITY RESIDENTS
    Mary Sano; Fiscal Year: 1992
    ..Parametric and non- parametric techniques will be used to assess drug effect. Endpoint analysis will use progression to dementia and functional independence measures...
  63. NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
    Robert Hubbard; Fiscal Year: 2002
    ..the CTN are delineated: 1) Multi-modal CBT for adolescent substance abusers with internalizing disorders and 2) Selegiline/CBT for cocaine dependence...
  64. NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
    Robert Hubbard; Fiscal Year: 2004
    ..the CTN are delineated: 1) Multi-modal CBT for adolescent substance abusers with internalizing disorders and 2) Selegiline/CBT for cocaine dependence...
  65. NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
    Robert Hubbard; Fiscal Year: 2003
    ..the CTN are delineated: 1) Multi-modal CBT for adolescent substance abusers with internalizing disorders and 2) Selegiline/CBT for cocaine dependence...
  66. NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
    Robert Hubbard; Fiscal Year: 2001
    ..the CTN are delineated: 1) Multi-modal CBT for adolescent substance abusers with internalizing disorders and 2) Selegiline/CBT for cocaine dependence...
  67. NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
    Robert Hubbard; Fiscal Year: 2002
    ..the CTN are delineated: 1) Multi-modal CBT for adolescent substance abusers with internalizing disorders and 2) Selegiline/CBT for cocaine dependence...
  68. NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
    Robert Hubbard; Fiscal Year: 2006
    ..the CTN are delineated: 1) Multi-modal CBT for adolescent substance abusers with internalizing disorders and 2) Selegiline/CBT for cocaine dependence...
  69. NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
    Robert Hubbard; Fiscal Year: 2006
    ..the CTN are delineated: 1) Multi-modal CBT for adolescent substance abusers with internalizing disorders and 2) Selegiline/CBT for cocaine dependence...
  70. NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
    Robert Hubbard; Fiscal Year: 2004
    ..the CTN are delineated: 1) Multi-modal CBT for adolescent substance abusers with internalizing disorders and 2) Selegiline/CBT for cocaine dependence...
  71. NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
    Robert Hubbard; Fiscal Year: 2001
    ..the CTN are delineated: 1) Multi-modal CBT for adolescent substance abusers with internalizing disorders and 2) Selegiline/CBT for cocaine dependence...
  72. NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
    Robert Hubbard; Fiscal Year: 2003
    ..the CTN are delineated: 1) Multi-modal CBT for adolescent substance abusers with internalizing disorders and 2) Selegiline/CBT for cocaine dependence...
  73. NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
    Robert Hubbard; Fiscal Year: 2005
    ..the CTN are delineated: 1) Multi-modal CBT for adolescent substance abusers with internalizing disorders and 2) Selegiline/CBT for cocaine dependence...